Dr. Baliga's 'Podkasts for Curious Docs'

Dr. Baliga's 'Podkasts for Curious Docs'

🧬 New insights into autism: A 2025 JCI Viewpoint highlights how hundreds of genes, polygenic risk, and specific environmental factors converge during fetal brain development to shape autism likelihood. 🧠 Early biomarkers—from infant MRI and ERPs to machine-learning models using EHR data—are accelerating earlier, more tailored interventions. 🌱 Advances in gene therapy, IGF-1 pathways, and proteomics offer emerging therapeutic possibilities. 🤝 Centering autistic voices remains essential as precision approaches evolve.

Dr. Baliga's 'Podkasts for Curious Docs'

🔍 Peripheral Neuropathy: What Clinicians Should Know 🧠⚡   Peripheral neuropathy affects ~1% of adults worldwide, with diabetes accounting for more than half of all cases. The JAMA review highlights why length-dependent patterns dominate, how metabolic stress injures long axons first, and why sensory symptoms outpace motor loss. Evidence-based evaluation still begins with glucose testing, vitamin B12 with methylmalonic acid, and serum protein electrophoresis.   First-line therapies for neuropathic pain — gabapentin, pregabalin, duloxetine, and tricyclics — offer meaningful...

Dr. Baliga's 'Podkasts for Curious Docs'

New NEJM insights on asymptomatic carotid stenosis 🧠🔍   The CREST-2 trials offer a landmark update: intensive medical therapy remains the cornerstone, while carotid stenting shows selective benefit when performed by expert operators. Endarterectomy, however, provides no significant advantage over modern medical management.   With stricter blood-pressure and LDL targets, plus expanding use of PCSK9 inhibitors, the future of stroke prevention is increasingly precision-driven, medically optimized, and patient-centered. 💊📉✨   A thoughtful read for all involved in...

Dr. Baliga's 'Podkasts for Curious Docs'

The new Lancet Series on ultra-processed foods offers a striking insight: as UPFs rise globally, traditional whole-food diets decline—bringing nutrient imbalance, overeating, toxic exposures, and hyper-palatable formulations that quietly reshape health trajectories. 🍔➡️⚠️   Across more than 100 prospective studies and multiple trials, higher UPF intake consistently links to obesity, type 2 diabetes, cardiovascular disease, kidney disease, depression, and higher all-cause mortality. 📉🩺   The message is clear: reducing UPF consumption isn’t a wellness...

Dr. Baliga's 'Podkasts for Curious Docs'

Home-delivered DASH-patterned groceries paired with dietitian counseling meaningfully lowered blood pressure and LDL cholesterol among Black adults living in food deserts 🥗📉—as demonstrated in the GoFresh randomized trial (JAMA).   An accompanying editorial highlights why future “food-as-medicine” programs must prioritize underconsumed, health-promoting foods and align with modern evidence favoring higher-fat DASH/Mediterranean patterns 🌱🫒.   A powerful reminder: the right groceries can be therapeutic.

Dr. Baliga's 'Podkasts for Curious Docs'

🩺 New insights in hemodialysis care. A major New England Journal of Medicine study reports that daily supplementation with long-chain omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) led to a 43% reduction in serious cardiovascular events among adults receiving maintenance hemodialysis. 🐟💙   In a population where traditional cardioprotective therapies often fall short, these findings open a fresh path for investigation — and perhaps, future practice. 📉🔬 A confirmatory trial will be essential, but the signal is compelling. 🌅

Dr. Baliga's 'Podkasts for Curious Docs'

🚀 A milestone moment in lipid therapeutics! The new JAMA trial on the oral PCSK9 inhibitor Enlicitide reports a ~60% reduction in LDL-C, with parallel decreases in ApoB and Lp(a)—all on top of maximally tolerated statin therapy.   For individuals with heterozygous familial hypercholesterolemia (HeFH)—where reaching LDL targets remains a persistent challenge—this represents a major advance. An oral agent matching the potency of injectable PCSK9 inhibitors could reshape adherence, access, and long-term ASCVD prevention. 🌉💊   Safety was comparable to placebo, and effects...

Dr. Baliga's 'Podkasts for Curious Docs'

☕ DECAF Trial insight! A new JAMA study shows that daily caffeinated coffee may lower recurrence of atrial fibrillation compared with abstinence. Patients drinking ~1 cup/day had 47% recurrence vs 64% with abstinence (HR 0.61, p=0.01) 📉💓 No major safety concerns—challenging long-held beliefs that coffee is proarrhythmic.   💡Takeaway: For many patients with AF, enjoying their morning brew may be both safe and possibly beneficial.   #AtrialFibrillation #Cardiology #JAMA #ClinicalTrials #HeartHealth ☕💓📊

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New insights from The Lancet 🚨   A major individual-patient-data meta-analysis (6 RCTs, 8,836 patients) shows that complete revascularisation in acute myocardial infarction significantly reduces cardiovascular death, all-cause mortality, and recurrent MI. 💓📉   Benefits were consistent across age, sex, STEMI/NSTEMI, and lesion characteristics — strengthening the case for a more comprehensive approach beyond the culprit lesion alone. 🔬🩺   A powerful reminder: treating the whole heart saves more lives. ❤️✨

Dr. Baliga's 'Podkasts for Curious Docs'

🧬 New NEJM data on Olezarsen! In patients with severe hypertriglyceridemia, monthly RNA-targeted therapy delivered major triglyceride reductions (−62% to −72%) and a significant drop in acute pancreatitis risk (rate ratio 0.15).   ✨ Improvements extended to ApoC-III, remnant cholesterol, and non-HDL cholesterol, with consistent benefits across both CORE-TIMI trials.   💡 A promising step forward in precision lipid therapy and pancreatitis prevention.